Insight Molecular Diagnostics Inc (IMDX) is a molecular diagnostics company that develops and commercializes diagnostic tests focused on organ transplant monitoring and oncology. Revenue comes from reimbursed diagnostic test procedures, with Medicare and third-party payers as the primary payment sources. The company's near-term commercial portfolio centers on five products: GraftAssureCore, GraftAssureIQ, GraftAssureDx, DetermaIO, and DetermaCNI, per the 10-K filed 2026-03-26. GraftAssureCore received a positive CMS coverage decision in August 2023, with CMS increasing reimbursement pricing in May 2025. DetermaIO and GraftAssureCore were available only in early access for non-clinical use as of the filing date. The company holds a collaboration arrangement with Bio-Rad for diagnostic test development and manufacturing. Research and development expenses were approximately $15.9 million in FY2025 and $9.8 million in FY2024. IMDX carries accumulated shareholders' deficit and has incurred net losses in both FY2025 and FY2024, with contingent consideration liabilities of $43.9 million as of December 31, 2025.

Revenue model

Reimbursement-based revenue from diagnostic test procedures, with Medicare (via MAC coverage and LCD approval) and private third-party payers as primary payment sources. Milestone payments and cost reimbursements from collaboration arrangements, including the Bio-Rad agreement, represent a secondary potential revenue source.

Products and services

GraftAssureCore (organ rejection surveillance, CMS-covered as of August 2023), GraftAssureIQ, GraftAssureDx (IVD clinical trial started FY2025), DetermaIO (early access, non-clinical use as of filing date), and DetermaCNI. All five products are in varying stages of development and commercialization as of the 10-K filed 2026-03-26.

Customers and end markets

Healthcare providers enrolled in the Medicare Fee-For-Service program (approximately 1.5 million providers in the program per the filing). End markets include organ transplant monitoring and oncology diagnostics. Payers include Medicare/CMS and private insurers such as health insurance companies and HMOs.

Value-chain role

Diagnostic test developer and laboratory services provider. The company develops proprietary molecular diagnostic tests, seeks Medicare and third-party payer reimbursement approvals, and relies on collaboration partners such as Bio-Rad for certain development and manufacturing functions.

Geographic exposure

Operations based in the United States, with foreign currency translation adjustments noted in financial statements indicating some international exposure. No specific non-U.S. revenue breakdown is supported by the filing excerpts.

Source: SEC 10-K, filed 2026-03-26

Industry: In Vitro & In Vivo Diagnostic Substances Peers: BIORA THERAPEUTICS, INC. Elutia Inc Candel Therapeutics Inc CytomX Therapeutics Inc Decibel Therapeutics, Inc. Immunic Inc Tourmaline Bio, Inc. vTv Therapeutics Inc